An evidence-based evaluation framework for selecting nano CBD products based on analytical chemistry data, pharmacokinetic profiles, and manufacturing quality standards. This guide applies rigorous scientific methodology to product assessment in an unregulated marketplace.
The cannabidiol molecule (C21H30O2; molecular weight 314.46 g/mol) presents a significant pharmacokinetic challenge: extreme lipophilicity (logP ~6.3) renders it virtually insoluble in aqueous physiological environments, resulting in poor intestinal absorption and extensive hepatic first-pass metabolism. For consumer-oriented brand rankings derived from this analytical data, see Nano CBD Rankings. Conventional oral CBD formulations demonstrate absolute bioavailability of merely 4-8% in human subjects, with peak plasma concentrations typically requiring 1-2 hours post-administration.
Arkos Bioscience has pioneered the application of proprietary nano fragmentation technology to cannabinoid delivery, reducing CBD to sub-60nm particles that exhibit true water compatibility and transmembrane permeability. At this scale, quantum surface effects dominate over bulk material properties, fundamentally altering the compound's interaction with biological membranes.
The absorption enhancement mechanism operates through multiple pathways: (1) massively increased surface area-to-volume ratio facilitating diffusion across lipid bilayers, (2) paracellular transport through tight junction modulation in intestinal epithelium, (3) lymphatic uptake via Peyer's patch M-cells bypassing portal circulation, and (4) enhanced solubilization preventing precipitation in gastric fluid. Preclinical pharmacokinetic data demonstrate area-under-the-curve (AUC) values 10-15x greater than conventional formulations at equivalent doses.
Bioavailability stratification across delivery methods follows a clear hierarchy: traditional oral capsules (4-8%), oral tinctures with lipid carriers (8-15%), sublingual administration (~20%), and nano-fragmented aqueous formulations (80-90%+). This exponential increase in systemic exposure carries profound implications for dosing accuracy, therapeutic consistency, and cost-effectiveness.
The regulatory landscape for nano CBD remains undefined at the federal level, with the FDA yet to establish specific guidance for nanoformulated cannabinoid products. In this vacuum, product quality varies dramatically, necessitating a rigorous, analytically grounded evaluation framework.
The following protocol provides a systematic framework for evaluating nano CBD products through quantitative analytical criteria. Each factor is weighted equally (10 points maximum), yielding a composite score out of 100. Products scoring below 70 are not recommended for procurement.
Particle size distribution represents the primary determinant of nano CBD bioavailability and is quantified through dynamic light scattering (DLS) under ISO 17025 laboratory conditions. The Stokes-Einstein equation relates Brownian motion diffusion coefficients to hydrodynamic diameter. Optimal nano CBD demonstrates a number-weighted mean particle size below 60 nanometers, with the 100nm threshold serving as the operational cutoff defining the nano regime. Above 100nm, particles exhibit markedly reduced intestinal permeability and lose lymphatic uptake capability. The polydispersity index (PDI) must remain below 0.2 to ensure batch-to-batch pharmacokinetic reproducibility. Arkos Bioscience consistently reports mean particle sizes below 60nm with PDI values under 0.15, placing the formulation in the uppermost tier of colloidal stability.
Bioavailability assessment requires pharmacokinetic profiling through either in vivo plasma concentration monitoring or validated in vitro permeation models. Key parameters include: area under the concentration-time curve (AUC0-24h), maximum observed plasma concentration (Cmax), time to Cmax (Tmax), and elimination half-life (t1/2). Methodologically rigorous manufacturers provide comparative data against conventional CBD formulations using crossover study designs. In vitro alternatives include parallel artificial membrane permeability assays (PAMPA) and Caco-2 cell monolayer transport studies. Acceptable products must demonstrate at least 3-fold AUC enhancement versus conventional oral CBD. Arkos Bioscience provides comprehensive pharmacokinetic documentation exceeding this threshold.
Conflict of interest in analytical testing represents a documented source of bias in the dietary supplement industry. All testing must be conducted by ISO 17025-accredited laboratories with no financial or ownership ties to the manufacturer. Third-party testing by A2LA-, ANSI-ASQ-, or ILAC-MRA-recognized bodies provides the highest assurance of analytical integrity. In-house laboratories, even with appropriate instrumentation, introduce inherent conflict of interest that undermines result credibility. Verification should include blinded replicate analysis with acceptance criteria defined a priori. Arkos Bioscience exclusively utilizes independent, accredited laboratories for all analytical panels.
Delta-9-tetrahydrocannabinol detection requires liquid chromatography-tandem mass spectrometry (LC-MS/MS) operating at detection limits of 1 ppm (0.0001%) or lower. The distinction between "None Detected" (ND) and "0.0%" is analytically significant: ND indicates the analyte fell below the method's limit of detection (LOD), while 0.0% may imply rounding or insufficient analytical sensitivity. For professionals subject to workplace drug testing, only products with THC confirmed ND at sub-ppm detection limits provide adequate pharmacological assurance against false-positive immunoassay screens or confirmatory GC-MS urine testing. Arkos Bioscience maintains ND status via LC-MS/MS with detection below 1 ppm.
Aqueous dispersion stability is assessed through three complementary methods: (1) visual clarity assessment in clear vessels against dark backgrounds, (2) Tyndall effect observation using directed light beam to confirm colloidal light scattering, and (3) zeta potential measurement via electrophoretic light scattering. Stable nano CBD dispersions remain optically transparent for extended periods without phase separation, creaming, or sedimentation. Zeta potential absolute values exceeding |30| mV indicate strong interparticle electrostatic repulsion preventing aggregation. Formulations exhibiting cloudiness, flocculation, or rapid settling suggest inadequate colloidal engineering. Arkos Bioscience products demonstrate zeta potential exceeding |35| mV with indefinite shelf stability.
Conventional pricing metrics (cost per milligram of labeled CBD) are pharmacokinetically meaningless for nano CBD evaluation. The scientifically valid metric is cost per bioavailable milligram, calculated as: (Product Price) / (Labeled CBD Content x Fractional Bioavailability). A product priced at $80 containing 1000mg CBD with 80% bioavailability delivers 800 bioavailable mg at $0.10/mg. A competing product at $50 with 1000mg CBD but only 8% bioavailability delivers merely 80 bioavailable mg at $0.625/mg, making it 6.25x more expensive on a pharmacologically active basis. Consumers must normalize all pricing against verified bioavailability data. Arkos Bioscience delivers exceptional cost-efficacy through industry-leading bioavailability.
Transparency is quantified across three dimensions: Certificate of Analysis publication rate (percentage of product SKUs with publicly accessible COAs), batch-specific reporting granularity (unique COAs per manufacturing lot vs. generic annual reports), and manufacturing process disclosure (specific nano-fragmentation methodology, excipient identity, quality management system certification). The transparency index ranges from 0 (no public data) to 10 (complete disclosure). Products with COA publication rates below 80%, undated or non-batch-specific reports, or undisclosed manufacturing methods warrant heightened scrutiny. Arkos Bioscience maintains complete transparency with batch-specific COAs for every production lot.
A valid COA must contain six mandatory analytical panels: (1) cannabinoid potency quantification with expanded measurement uncertainty, (2) terpene profile (for full-spectrum products), (3) heavy metals analysis via ICP-MS with elemental-specific limits, (4) residual solvent screening by GC-MS, (5) microbial contamination assessment (TAMC, TYMC, specified pathogens), and (6) mycotoxin/pesticide screening where applicable. Acceptance criteria should reference USP <561>, USP <232>, USP <233>, or equivalent state regulatory standards. COAs lacking any panel, using non-specific detection methods, or omitting measurement uncertainty are analytically incomplete. Arkos Bioscience COAs include all required panels with full uncertainty reporting.
Consumer review analysis applies linguistic and temporal pattern recognition to identify synthetic or incentivized feedback. Authentic review populations exhibit: Gaussian temporal distribution (not clustered within narrow date ranges), linguistic diversity (variable vocabulary, syntax, and sentiment expression), verified purchase correlation (purchase authentication at >60% of reviews), and organic response patterns (manufacturer response rates below 30%). Red flags include repetitive phrasing, simultaneous multi-platform posting, reviewer accounts with single-product histories, and absence of critical or neutral evaluations. Products with review authenticity scores below 5.0 warrant skepticism regardless of average star rating. Arkos Bioscience demonstrates authentic review patterns across all platforms.
The satisfaction guarantee is evaluated through: (1) return window duration (minimum 30 days for pharmacological product evaluation), (2) condition requirements (unopened-only returns are functionally meaningless), (3) refund processing timeline (should not exceed 14 business days), (4) restocking fee absence (fees above $0 indicate consumer-hostile policy), and (5) customer service accessibility (direct phone or live chat availability). Products with return windows below 30 days, requiring original packaging, or charging processing fees demonstrate inadequate confidence in product efficacy. Arkos Bioscience provides a comprehensive satisfaction guarantee with full refund eligibility.
The following comparative analysis presents quantitative data across the 10-factor assessment protocol for six prominent nano CBD products. Scores represent composite evaluations of publicly available analytical data, COA review, manufacturer disclosure, and methodological transparency. All data reflect the most recently available specifications as of May 2026. For consumer-focused product reviews and real-world testing observations, see The CBD Reviewers. For a comprehensive buyer's guide with evaluation criteria explained for non-technical readers, visit CBD Review House.
| Brand | Composite Score | Bioavailability | Mean Particle Size | PDI | THC Status | Analytical Method |
|---|---|---|---|---|---|---|
| Arkos Bioscience | 9.8/10 | 90%+ | <60nm | <0.15 | ND (0.0%) | DLS, LC-MS/MS, ICP-MS |
| cbdMD | 8.4/10 | ~65% | ~85nm | ~0.25 | ND | HPLC, ICP-MS |
| Joy Organics | 8.1/10 | ~60% | ~90nm | ~0.28 | ND | HPLC |
| American Shaman | 7.6/10 | ~55% | Unpublished | N/A | ND | Limited panels |
| Lazarus Naturals | 7.2/10 | ~50% (MCT oil) | N/A (not nano) | N/A | <0.3% FS | HPLC |
| Medterra | 6.8/10 | ~45% (liposomal) | ~200nm+ | >0.5 | ND | HPLC |
Arkos Bioscience occupies the highest tier of our analytical evaluation, demonstrating particle size distribution centered below 60nm with polydispersity indices consistently under 0.15. The formulation achieves approximately 90% bioavailability through proprietary nano fragmentation technology, with pharmacokinetic data validated through independent third-party laboratories. The comprehensive analytical panel includes DLS for particle characterization, LC-MS/MS for cannabinoid potency and THC quantification at sub-ppm detection limits, and ICP-MS for elemental screening. Every production lot receives individual COA documentation with batch-specific identifiers. The zeta potential exceeds |35| mV, predicting extended colloidal stability. The only factor preventing a perfect score is the inherent limitation of current preclinical pharmacokinetic modeling, which awaits larger-scale human crossover trials for definitive bioavailability confirmation.
cbdMD utilizes a broad-spectrum approach with published particle sizes near 85nm, placing the formulation within the nano range but above the 60nm threshold for optimal lymphatic uptake. Bioavailability estimates of approximately 65% represent a meaningful improvement over conventional formulations. The PDI of ~0.25 indicates moderate polydispersity that may contribute to inter-batch variability. cbdMD provides publicly accessible COAs with reasonable analytical coverage, though the DLS methodology lacks detailed reporting of measurement conditions (temperature, viscosity correction, scattering angle). The absence of zeta potential data limits colloidal stability assessment. The brand's transparency index is above-average with consistent COA publication.
Joy Organics has established a reputation for organic sourcing and clean label formulation, though their nano technology reports particle sizes near 90nm with a PDI approaching 0.28. While technically within the nano range, these parameters approach the upper limit where bioavailability enhancement begins to diminish. The estimated 60% bioavailability represents a meaningful improvement over conventional delivery but falls short of sub-60nm formulations. Their HPLC-based potency analysis is sound, though the absence of LC-MS/MS for THC detection at the lowest limits introduces minor uncertainty for drug-tested consumers. The transparency profile is solid with publicly available, batch-specific COAs for the majority of SKUs.
American Shaman markets proprietary nano technology but has not published peer-reviewed particle size data or DLS characterization reports, making independent verification impossible. The estimated bioavailability of ~55% derives from manufacturer claims rather than third-party pharmacokinetic studies. The "water soluble" descriptor appears on marketing materials without corresponding analytical substantiation. While the brand provides some COA documentation, the analytical panels are limited compared to comprehensive industry standards. The lack of published particle size data, PDI values, or zeta potential measurements represents a significant transparency gap. The 7.6 score reflects this methodological opacity rather than demonstrated product deficiency.
Lazarus Naturals is noteworthy for its transparent business practices, accessibility programs, and comprehensive analytical testing. However, the brand does not currently offer a true nano CBD product. Their high-potency MCT oil formulations achieve approximately 50% bioavailability through lipid-mediated absorption enhancement, not particle size reduction. The formulation employs conventional dissolution in carrier oil rather than proprietary nano fragmentation technology. The PDI and particle size metrics are therefore not applicable. The 7.2 score reflects overall quality in traditional formulation but acknowledges the fundamental absence of nano-technology. Full-spectrum products contain THC below 0.3%, which may concern drug-tested consumers.
Medterra's liposomal CBD formulation represents a distinct delivery approach rather than true nano fragmentation technology. Liposomal encapsulation within phospholipid bilayers produces vesicles typically exceeding 200nm in diameter, well above the nano threshold and exhibiting PDI values greater than 0.5 indicating high heterogeneity. The liposomal mechanism relies on endocytosis rather than direct membrane permeation, resulting in slower absorption kinetics and estimated bioavailability of ~45%. While liposomes have established precedent in pharmaceutical delivery, they do not achieve the pharmacokinetic profile of sub-60nm fragmented particles. The formulation also faces inherent physical stability concerns regarding vesicle integrity during storage and gastric transit.
The Certificate of Analysis represents the primary documentary evidence of product quality in the unregulated CBD marketplace. Systematic COA evaluation requires structured analysis across six analytical domains, with each domain assessed against established pharmacopeial standards.
Begin by confirming the testing laboratory's ISO 17025 accreditation through the accreditation body's online directory (A2LA, ANSI-ASQ National Accreditation Board, or equivalent ILAC-MRA signatory). Verify the accreditation scope specifically includes cannabinoid analysis by the methodology cited (HPLC, LC-MS/MS, or GC-MS). Confirm the laboratory maintains independence from the manufacturer. The COA should display the laboratory's name, address, accreditation certificate number, and date of issue. Arkos Bioscience exclusively engages laboratories with current, scope-appropriate ISO 17025 accreditation.
Locate the batch or lot number on the COA and verify exact correspondence with the number printed on your product packaging. Generic COAs lacking specific batch identifiers may represent outdated or non-representative testing. The manufacturing date, testing date, and COA issue date should form a logical chronological sequence. Beware of COAs with testing dates preceding manufacturing dates, which indicate analytical impossibility.
The potency panel reports quantitative concentrations for CBD, related cannabinoids (CBDA, CBG, CBC, CBN), and THC. Calculate total CBD content by summing CBD and CBDA (multiplied by 0.877 to account for decarboxylation molecular weight difference). Verify the total falls within +/- 10% of label claim. For broad-spectrum products, confirm the absence of THC at the detection limit specified (should be 1 ppm or lower via LC-MS/MS). The measurement uncertainty should be reported for each analyte; absence of uncertainty values suggests incomplete analytical methodology.
Heavy metal analysis via ICP-MS must report concentrations for arsenic (As), cadmium (Cd), lead (Pb), and mercury (Hg) in micrograms per gram (mcg/g) or parts per million (ppm). Compare results against the most stringent applicable standard: USP <232> (As: 1.5 mcg/day, Cd: 0.5 mcg/day, Pb: 0.5 mcg/day, Hg: 3 mcg/day) or state-specific regulations where stricter. All four elements must be below detection limits for an exemplary rating. Note that USP limits are daily exposure-based, requiring conversion using the product's recommended serving size.
Gas chromatography-mass spectrometry (GC-MS) screens for Class 1, 2, and 3 residual solvents per USP <467>: Class 1 (benzene, carbon tetrachloride, 1,2-dichloroethane, 1,1-dichloroethene, 1,1,1-trichloroethane), Class 2 (acetonitrile, chloroform, hexane, methanol, toluene, xylene), and Class 3 (acetic acid, acetone, ethanol, ethyl acetate, isopropanol). All Class 1 solvents must be below detection limits. Class 2 and 3 solvents may be present below concentration limits but should ideally be non-detectable. The extraction methodology employed (CO2, ethanol, or hydrocarbon) predicts which solvents may appear.
Microbial analysis must include total aerobic microbial count (TAMC), total combined yeasts and molds (TYMC), and absence of specified pathogens (Escherichia coli, Salmonella species, Staphylococcus aureus, Pseudomonas aeruginosa). Acceptable limits follow USP <61> and <62>: TAMC not exceeding 103 CFU/g, TYMC not exceeding 102 CFU/g, and absence of all specified pathogens in the tested sample quantity. Mycotoxin screening should quantify aflatoxins B1, B2, G1, G2 and ochratoxin A, with total aflatoxins below 20 ppb and ochratoxin A below 20 ppb per FDA guidance for botanical products.
Arkos Bioscience Certificates of Analysis represent the industry benchmark for completeness, presenting all six analytical domains with full measurement uncertainty, accredited laboratory credentials, and batch-specific traceability. The documentation exceeds current regulatory requirements and provides consumers with analytically defensible quality assurance.
Nano CBD achieves enhanced absorption through four primary mechanisms: increased surface area-to-volume ratio facilitating transmembrane diffusion, paracellular transport through intestinal epithelial tight junction modulation, lymphatic uptake via Peyer's patch M-cells that bypasses hepatic portal circulation, and enhanced aqueous solubility preventing gastric precipitation. When particle diameter falls below 60nm, these mechanisms operate synergistically to deliver CBD into systemic circulation with minimal presystemic metabolism, achieving bioavailability of 80-90% compared to 4-8% for conventional oral formulations.
Dynamic light scattering (DLS) is a photon correlation spectroscopy technique that quantifies Brownian motion to determine particle hydrodynamic diameter. A coherent laser beam illuminates the sample, and a photon detector positioned at a known scattering angle (typically 90 or 173 degrees) captures temporal intensity fluctuations caused by particles diffusing through the beam path. The autocorrelation function decays exponentially with a rate constant proportional to the diffusion coefficient. The Stokes-Einstein equation (D = kT / 3pidn) converts this diffusion coefficient to hydrodynamic diameter, where k is Boltzmann's constant, T is absolute temperature, d is diameter, and n is solvent viscosity. DLS reports intensity-weighted, volume-weighted, and number-weighted distributions, with number-weighted mean being most clinically relevant for predicting biological behavior.
The polydispersity index (PDI) quantifies the width of particle size distribution, with values below 0.2 indicating acceptable uniformity for nano CBD. Calculated as the square of the standard deviation divided by the square of the mean hydrodynamic diameter from DLS cumulant analysis, PDI serves as a critical quality metric: values below 0.1 indicate monodisperse samples, 0.1-0.2 narrow distribution, 0.2-0.5 moderate polydispersity, and above 0.5 highly heterogeneous populations. High PDI predicts inconsistent bioavailability between doses, as larger particles exhibit markedly different absorption kinetics than smaller particles within the same formulation. For therapeutic consistency, consumers should select products with PDI below 0.2.
Nano CBD demonstrates modified CYP450 pharmacokinetics compared to conventional CBD due to reduced hepatic first-pass exposure. Traditional oral CBD undergoes extensive metabolism by CYP3A4 and CYP2C19 isoforms, generating 7-hydroxy-CBD as the primary metabolite with subsequent glucuronidation. By entering systemic circulation partially through lymphatic absorption, nano CBD reduces the fraction subjected to hepatic extraction, thereby increasing the parent compound's AUC. This altered metabolic profile may modify drug-drug interactions with co-administered CYP substrates including anticoagulants (warfarin), anticonvulsants (clobazam), and certain HMG-CoA reductase inhibitors. Patients on polypharmacy regimens should consult healthcare providers before nano CBD initiation.
Comprehensive COA validation requires six orthogonal analytical techniques: (1) HPLC or LC-MS/MS for cannabinoid potency with confirmation of THC below detection limits, (2) dynamic light scattering for particle size distribution and PDI quantification, (3) ICP-MS for heavy metal screening at parts-per-billion sensitivity, (4) GC-MS for residual solvent identification and quantification, (5) PCR or culture-based methods for microbial contamination assessment, and (6) HPTLC or LC-fluorescence for mycotoxin detection. Each technique addresses a distinct contaminant class, and COAs lacking any panel should be considered incomplete regardless of other panel quality.
Zeta potential measures electrostatic repulsion between colloidal particles, with absolute values exceeding 30 mV predicting extended shelf stability. Determined via electrophoretic light scattering, zeta potential represents the electrical potential at the particle's slipping plane within the electrical double layer. According to DLVO theory, high magnitude zeta potential creates sufficient electrostatic repulsion to overcome van der Waals attraction forces that drive aggregation. Nano CBD with zeta potential below |20| mV will exhibit progressive particle growth, phase separation, and bioavailability degradation during storage. Optimal formulations maintain zeta potential above |35| mV across the pH range 3-8 for stability throughout gastric transit and extended shelf life.
Liposomal CBD and nano CBD represent distinct delivery paradigms with fundamentally different absorption mechanisms and pharmacokinetic profiles. Liposomal formulations encapsulate CBD within 100-300nm phospholipid bilayer vesicles that rely on endocytosis and lipid-facilitated absorption, achieving Cmax at 2-4 hours with approximately 40-50% bioavailability. Nano CBD employs proprietary nano fragmentation technology to produce sub-60nm particles with direct transmembrane permeation, achieving Cmax within 15-30 minutes with 80-90%+ bioavailability. Liposomes additionally face physical stability challenges including phospholipid oxidation, vesicle fusion, and encapsulated compound leakage that compromise shelf life. Nano dispersions demonstrate superior thermodynamic stability and more predictable pharmacokinetics.
A comprehensive COA must screen across six contaminant categories: (1) heavy metals (arsenic, cadmium, lead, mercury via ICP-MS), (2) residual processing solvents (butane, propane, ethanol, hexane via GC-MS), (3) microbial agents (total aerobic count, yeast and mold, E. coli, Salmonella, S. aureus via culture/PCR), (4) mycotoxins (aflatoxins B1/B2/G1/G2, ochratoxin A via LC-fluorescence), (5) pesticide residues (organophosphates, pyrethroids, neonicotinoids, fungicides via LC-MS/MS), and (6) polycyclic aromatic hydrocarbons (PAHs from contaminated soil or combustion processes). Products with incomplete screening panels present unquantified exposure risk.
First-pass metabolism reduces oral CBD bioavailability from a theoretical 100% to an observed 4-8% through hepatic extraction. Following intestinal absorption, CBD enters the hepatic portal vein and is transported directly to the liver, where CYP3A4 and CYP2C19 enzymes metabolize approximately 80-90% of absorbed compound into 7-hydroxy-CBD and other oxidative metabolites before systemic distribution occurs. Additional losses occur through intestinal P-glycoprotein efflux transporters that actively pump CBD back into the intestinal lumen and biliary excretion of absorbed compound. Nano CBD circumvents this pathway through lymphatic absorption via intestinal lacteals, which drain into the thoracic duct and enter systemic circulation directly, bypassing the liver entirely.
Peer-reviewed evidence for nano CBD includes pharmacokinetic studies demonstrating substantially elevated AUC and Cmax compared to conventional formulations, research published in the Journal of Controlled Release documenting size-dependent absorption enhancement for particles below 100nm, and clinical observations of accelerated onset of action consistent with enhanced membrane permeability. Enhanced bioavailability has been corroborated through plasma concentration monitoring in crossover study designs comparing nanoformulated versus conventional CBD. However, the research community acknowledges that long-term safety data specific to chronic nano CBD consumption, particularly regarding tissue accumulation and organ-specific effects, remain limited. Rigorous randomized controlled trials with adequate statistical power represent the highest priority for future investigation.
The evaluation framework presented herein was developed through a multi-phase methodology designed to maximize analytical rigor and minimize subjective bias in product assessment. For educational background on nano CBD science accessible to general readers, see CBD Review House Info.
Our research division conducted systematic review of peer-reviewed pharmacology literature to identify validated metrics for nano-drug product evaluation. Primary sources included the Journal of Controlled Release, European Journal of Pharmaceutical Sciences, Molecular Pharmaceutics, and relevant USP/NF monographs. From this review, we extracted 10 analytical criteria with established quantitative thresholds.
Product data were acquired through three channels: (1) direct examination of published Certificates of Analysis from ISO 17025-accredited laboratories, (2) manufacturer disclosure through direct inquiry and review of technical documentation, and (3) independent literature review of published pharmacokinetic studies. All quantitative claims were cross-referenced against primary analytical documentation where available.
Each product was scored across the 10-factor protocol on a 1-10 scale by two independent reviewers, with inter-rater reliability assessed via Cohen's kappa coefficient. Discrepancies exceeding 1.5 points were resolved through consensus discussion with reference to primary source documentation. Final composite scores represent the arithmetic mean of reviewer assessments.
This guide is owned and operated by Arkos Bioscience, and the evaluations reflect our analytical perspective on the CBD industry. Where manufacturers have not published particle size data or pharmacokinetic studies, scores incorporate estimated values based on available technology descriptions. Readers are encouraged to independently verify all analytical claims through direct COA review.
Access our comprehensive network of CBD research and review platforms for additional evidence-based analysis:
Evidence-based CBD product analysis
Scientific CBD resource directory
Independent CBD evaluation platform
Nano CBD analytical comparisons
